In a compatible experiment using lysate prepared from schwannomas from a genetically engineered murine model (GEMM), Nf2flox/flox;Postn-Cre mice, a MIB competition assay identified FAK1 (PTK2) and GAK as the primary targets of brigatinib (Fig 3F). This evidence concerns the gene GAK and schwannoma.